Balaxi Pharmaceuticals Limited (Balaxi), a branded IPR-based pharmaceutical company headquartered in Hyderabad, has recorded a revenue of Rs. 53 crore for Q4 FY21. 

The drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday. 

The company has reported EBITDA of Rs. 10 crore for Q4 FY21 and PAT of Rs. 8.4 crore for Q4 FY21. For Q4 FY21, the Pharmaceutical business segment contributed 58% of the consolidated revenues and 72% of the total gross profit. Share of the Pharmaceuticals business in total revenue increased on account of higher contributions from Guatemala and Dominican Republic. 

Ancillary business contributed 24% to the revenue in Q4 FY21 and 28% in FY21. Share of YAP branded consumer products revenue increased from 13% in Q3 FY21 to 18% in Q4FY21. Biscuits continues to remain a major contributor in this segment, contributing more than 90% of revenue from this segment. 

Commenting on the performance, Ashish Maheshwari, Chairman and Managing Director said, “Balaxi set its footprints into the newer geography of Nicaragua, with a registration pipeline of 90 products which reflects the company’s ‘Land and Expand’ strategy. As on date Balaxi has 552 pharmaceutical product registrations/import permits, spanning across 5 countries, and has a pipeline of 672 product registrations spanning across 6 countries." 

"Balaxi saw an increase in the share of pharmaceutical business from Guatemala and Dominican Republic, showcasing that the newer geographies have started contributing in the company’s overall pharmaceutical segment. The company remains confident about achieving its long-term growth aspiration and looks forward to expanding in additional geographies. Balaxi aims to expand in 20 frontier markets over the next 5 years,” commented Maheshwari.